Monoterpene substituted thiazolidin-4-ones as novel TDP1 inhibitors: Synthesis, biological evaluation and docking

Bioorg Med Chem Lett. 2022 Oct 1:73:128909. doi: 10.1016/j.bmcl.2022.128909. Epub 2022 Jul 27.

Abstract

Tyrosyl-DNA phosphodiesterase 1(TDP1) is a promising target for a new therapy in oncological disease as an adjunct to topoisomerase 1 (TOP1) drugs. In this paper, novel thiazolidin-4-one derivatives with a benzyl and monoterpene substituents were synthesized. Compounds with a monoterpene fragment attached via a phenyloxy linker were active against TDP1 with IC50 values in the 1 ÷ 3 μM range, while direct attachment of monoterpene moiety to the thiazolidin-4-one fragment had no activity. Molecular modelling predicted two plausible binding modes of the active compounds both effectively blocking access to the catalytic site of TDP. At non-toxic concentrations the active ligands potentiated the efficacy of the TOP1 poison topotecan in human cervical cancer HeLa cells, but not in non-cancerous HEK293A cells.

Keywords: Monoterpenic derivatives; TDP1 inhibitors; Thiazolidin-4-ones; Tyrosyl-DNA phosphodiesterase 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Esterases / metabolism
  • HeLa Cells
  • Humans
  • Monoterpenes / pharmacology
  • Phosphodiesterase Inhibitors* / pharmacology
  • Phosphoric Diester Hydrolases* / metabolism
  • Structure-Activity Relationship

Substances

  • Monoterpenes
  • Phosphodiesterase Inhibitors
  • Esterases
  • Phosphoric Diester Hydrolases
  • TDP1 protein, human